Evaluation
*
*

Thinking about the impact of this session on your patients, please offer an estimate of the:

*
%
*
/month
*
1 (Disagree)2345 (Agree)
Recall updated clinical practice guidelines regarding genetic testing for targetable mutations in patients with metastatic NSCLC
Discuss efficacy and safety data from recent clinical trials of kinase inhibitors targeted against EGFR mutations and ALK rearrangements
Comment on best practices for managing side effects associated with EGFR and ALK inhibitors
Apply recommended procedures for identifying and overcoming the T790M acquired resistance mutation
*
1 (Low)2345 (High)
Heather Wakelee, MD
Elizabeth Waxman, RN, MSN, AOCN, ANP-BC
*
*